Gland Pharma Limited (GLAND) Operating Income 2023–2026

Name: Gland Pharma Limited (GLAND) operating income history 2023-2026
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-09-20

Gland Pharma Limited annual operating income for fiscal 2026 was ₹12.1 billion, an increase of 35.6% from ₹8.9 billion in fiscal 2025. All figures are reported results from public filings — no estimates or projections.

GLAND Annual Operating Income

Operating Income (annual)	2026-03-31	2025-03-31	2024-03-31	2023-03-31
Operating Income (EBIT)	₹12.1B	₹8.9B	₹10.0B	₹8.7B

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

GLAND Quarterly Operating Income

Operating Income (quarterly)	2026-06-30	2026-03-31	2025-12-31	2025-06-30	2025-03-31
Operating Income (EBIT)	₹3.8B	₹4.0B	₹3.3B	₹2.7B	₹2.5B

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Operating Income at Comparable Companies

GLENMARK Operating Income — Glenmark Pharmaceuticals Limited
ALKEM Operating Income — Alkem Laboratories Limited
ABBOTINDIA Operating Income — Abbott India Limited
IPCALAB Operating Income — Ipca Laboratories Limited
AJANTPHARM Operating Income — Ajanta Pharma Limited
EMCURE Operating Income — Emcure Pharmaceuticals Limited

More GLAND metrics: Revenue · Gross Profit · Net Income · EPS · Free Cash Flow

All GLAND financial statements → Interactive GLAND charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.